Arlington Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Arlington Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3	Closed	-$2.47K	–	362
2023 Q3	$2.47K	Hold	3	–	–	﹤0.01%	270
2023 Q2	$2.16K	Sell	3 -10	-77%	-$7.71K	﹤0.01%	531
2023 Q1	$10.7K	Buy	+13	New	+$9.8K	﹤0.01%	413
2022 Q1	–	Sell	-21	Closed	-$13K	–	615
2021 Q4	$13K	Sell	21 -78	-79%	-$48K	﹤0.01%	440
2021 Q3	$60K	Buy	+99	New	+$61.5K	0.02%	241
2020 Q2	–	Sell	-15	Closed	-$7K	–	267
2020 Q1	$7K	Buy	15 +8	+114%	+$3.3K	﹤0.01%	172
2019 Q4	$3K	Buy	+7	New	+$2.35K	﹤0.01%	239
2019 Q1	–	Sell	-7	Closed	-$3K	–	233
2018 Q4	$3K	Buy	+7	New	+$2.56K	﹤0.01%	198

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Arlington Partners's REGN Position: Q4 2023 in Review

Arlington Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 3 shares — an estimated $2.47K sold.

Arlington Partners first reported a position in REGN in Q4 2018 and held it in 8 quarters. The position peaked at $60K in Q3 2021. 1,273 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

Arlington Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Arlington Partners sold 3 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $2.47K.
Arlington Partners first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 8 quarters.
Arlington Partners's Regeneron Pharmaceuticals position peaked at $60K in Q3 2021.
1,273 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on Arlington Partners's 13F filing for Q4 2023, filed 24 Jan 2024.